Core Insights - StratifAI, an AI precision oncology company, has been selected for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program, which will enhance its capabilities in biomarker validation [1] Company Summary - The engagement with MSK will provide StratifAI access to extensive clinical datasets, facilitating collaboration with leading clinicians and researchers [1] - The Polaris™ platform, developed by StratifAI, aims to establish a new standard in biomarker validation [1]

Core Insights - StratifAI, an AI precision oncology company, has been selected for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program, which will enhance its capabilities in biomarker validation [1] Company Summary - The engagement with MSK will provide StratifAI access to extensive clinical datasets and opportunities for collaboration with leading clinicians and researchers [1] - The Polaris™ platform, developed by StratifAI, aims to establish a new standard in biomarker validation [1]